Kiara acquired the internationally GMP compliant Novartis plant, and twenty-six marketing authorisations (MAs) from Novartis’ subsidiary generic drugs manufacturer, Sandoz South Africa, contract manufacturing selected products for Sandoz SA for a four-year period.